| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2010: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2009: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2008: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Research Abstract |
We focused on the phenomenon CD20-negative phenotypic change after performing chemotherapies with rituximab in CD20-positive B-cell lymphoma cells, and the molecular mechanisms of CD20-negative change were analyzed. It appears that aberrant down-regulation of MS4A1 gene expression is closely related to CD20-negative phenotype, and the repression may be introduced by recruitment of Sin3-HDAC1 protein complex to MS4A1 promoter region. CD20-negative phenotype is related to resistance to rituximab therapy. Down-regulated CD20 expression can be partially stimulated by epigenetic drugs resulting in partial restoration of rituximab sensitivity.
|
